[1] Humphrey P A, Moch H, Cubilla A L, et al.The 2016 WHO classification of tumors of the urinary system and male genital organs-Part B:prostate and bladder tumors[J].Eur Urol, 2016, 70 (1):106-119.
[2] Kovi J, Jackson M A, Heshmat M Y, et al.Ductal spread in prostatic carcinoma[J].Cancer,1985,56(7):1566-1573.
[3] McNeal J E, Yemoto C E.Spread of adenocarcinoma within prostatic ducts and acini:morphologic and clinical correlations[J].Am J Surg Pathol, 1996, 20(7):802-814.
[4] Samaratunga H, Delahunt B.Egevad L Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded[J].Pathology, 2020, 52(2):192-196.
[5] van Leenders G, van der Kwast T H, Grignon D J, et al.The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on grading of prostatic carcinoma[J].Am J Surg Pathol, 2020, 44(8):e87-e99.
[6] Robinson B D, Epstein J I.Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy:emphasis on radical prostatectomy findings[J].J Urol,2010, 184(4):1328-1333.
[7] Porter L H, Lawrence M G, Ilic D, et al.Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories[J].Eur Urol,2017, 72(4):492-495.
[8] Epstein J.Is there enough support for a new prostate grading system factoring in intraductal carcinoma and cribriform cancer?[J].Eur Urol, 2020, 77(2):199-200
[9] Gandhi J S, Smith S C, Paner G P, et al.Reporting practices and resource utilization in the era of intraductal carcinoma of the prostate-a survey of genitourinary subspecialists[J].Am J Surg Pathol, 2020, 44(5):673-680.
[10] Humphrey P A, Moch H, Cubilla A L, et al.The 2016 WHO classification of tumours of the urinary system and male genital organs-part B:prostate and bladder tumours[J].Euro Urol, 2016, 70(1):106-119.
[11] 何为,马闰卓,卢剑,等.前列腺导管内癌的研究进展[J].中华泌尿外科杂志,2019,40(4):314-317.
[12] 赖亚明,韩斌,吴斌.Gleason评分对前列腺癌转归预测意义[J].中华肿瘤防治杂志,2018,25(13):951-955.
[13] 陈玉玲,樊翔,王国庆, 等.前列腺导管内癌的病理特征及临床意义[J].诊断病理学杂志,2019,26(9):595-599.
[14] Epstein J I, Egevad L, Amin M B, et al.The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma:definition of grading patterns and proposal for a new grading system[J].Am J Surg Pathol,2016,40(2):244-252.
[15] Watts K, Li J, Magi-Galluzzi C, et al.Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies:a prospective cohort study[J].Histopathology, 2013, 63(4):574-579.
[16] 赵劲歌,聂玲,陈雪琴, 等.前列腺导管内癌对转移性前列腺癌各亚组患者的预后影响[J].中华泌尿外科杂志,2019,57(6):422-427.
[17] Khani F, Epstein J I.Prostate biopsy specimens with Gleason 3+3=6 and intraductal carcinoma:radical prostatectomy findings and clinical outcomes[J].Am J Surg Pathol, 2015, 39(10):1383-1389.
[18] Lindberg J, Kristianaen A, Wiklund P, et al.Tracking the origin of metastatic prostate cancer[J].Eur Urol, 2015, 67(5):819-822.
[19] Zhao J, Shen P, Sun G, et al.The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy[J].Oncotarget,2017, 8(15):55374-55383.
[20] Kato M, Hirakawa A, Kobayashi Y, et al.Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients[J].Prostate, 2020, 80(3):284-290.
[21] Lam T B L, MacLennan S, Willemse P M, et al.EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study)[J].Eur Urol,2019, 76(6):790-813.
[22] Montironi R, Zhou M, Magi-Galluzzi C, et al.Features and prognostic significance of intraductal carcinoma of the prostate[J].Eur Urol Oncol,2018, 1(1):21-28. |
